GDF15 and hepatocellular carcinoma: HCC patients with higher serum GDF15 tended to have poorer clinical responses (stable disease, SD; and progressive disease, PD), whereas patients who achieved a complete response (CR) or partial response (PR) generally had lower serum GDF15 levels (Figure 2A).